Cyclacel Pharmaceuticals ...

0.21
-0.02 (-8.70%)
At close: Apr 04, 2025, 3:59 PM
0.23
7.45%
Pre-market: Apr 07, 2025, 05:06 AM EDT
-8.70%
Bid 0.22
Market Cap 44.37M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -27.4
PE Ratio (ttm) -0.01
Forward PE -0.18
Analyst Buy
Ask 0.24
Volume 197,178
Avg. Volume (20D) 554,580.3
Open 0.22
Previous Close 0.23
Day's Range 0.20 - 0.23
52-Week Range 0.20 - 4.00
Beta 0.16

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 16, 2004
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CYCC
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 5040.19% from the latest price.

Stock Forecasts

Earnings Surprise

Cyclacel Pharmaceuticals has released their quartely earnings on Apr 2, 2025:
  • Revenue of $0 misses estimates by $10K, with -100.00% YoY decline.
  • EPS of -0.33 misses estimates by -0.04, with 94.70% YoY growth.
  • Next Earnings Release

    Cyclacel Pharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 months ago
    +24.02%
    Cyclacel Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
    4 months ago
    +9.76%
    Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.